Medgenics kicks of clinical trial of hepatitis treatment

Medgenics has enrolled the first patient for its clinical trial of its INFRADURE Biopump product, which is used for the treatment of hepatitis C.

Medgenics has enrolled the first patient for its clinical trial of its INFRADURE Biopump product, which is used for the treatment of hepatitis C.

INFRADURE is a subcutaneous autologous skin tissue implant for the continuous production and delivery of interferon-alpha (INFa )needed by hepatitis patients.

It was developed by Medgenics to treat hepatitis B, C and D, to replace months of weekly injections of INFa, along with the serious side effects.

The initial phase of the study is being conducted at the Tel Aviv Sourasky Medical Center in Israel.

The study is recruiting patients with hepatitis C of genotypes 2 and 3, who would normally receive weekly injections of INFa together with a daily dose of the oral antiviral drug ribavirin.

Patients will receive a single implantation of INFRADURE Biopumps in place of the weekly injections, together with daily ribavirin.

"Medgenics believes that the results of this study will assist in developing and calibrating INFRADURE for use in additional types of viral hepatitis, as well as other indications," the company said.

RD

Recommended

The top funds to invest in
Funds

The top funds to invest in

As market volatility and recessionary fears continue, here are the most popular funds, stocks and trusts investors are putting their money into
2 Mar 2023
The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves takes a look at the companies with the highest dividend yields in the UK’s blue-chip index
27 Feb 2023
The outlook for Shell shares is mixed, despite bumper profits
Energy stocks

The outlook for Shell shares is mixed, despite bumper profits

With profits surging, it looks as if Shell is on a roll, but the company’s growth from here is hard to see as Rupert Hargreaves explains.
6 Feb 2023
The top ten dividend stocks in the FTSE 250
Share tips

The top ten dividend stocks in the FTSE 250

The average FTSE 250 dividend yield is around 4%, but many stocks yield much more. Rupert Hargreaves picks the best FTSE 250 stocks for income investo…
17 Jan 2023

Most Popular

Five changes to state pensions coming next month
Pensions

Five changes to state pensions coming next month

There are several changes happening to state pensions in April. We explain what’s happening.
22 Mar 2023
When will interest rates go up?
UK Economy

When will interest rates go up?

The Bank of England raised rates to 4.25%, its 11th consecutive increase. Does the base rate have further to go?
23 Mar 2023
Will energy prices go down in 2023?
Personal finance

Will energy prices go down in 2023?

Ofgem’s price cap is now predicted to fall below £2,000, based on average typical use, from July, for the first time since 2022. We have all the detai…
21 Mar 2023